These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 19574030)

  • 1. Frontal EEG predictors of treatment outcome in major depressive disorder.
    Iosifescu DV; Greenwald S; Devlin P; Mischoulon D; Denninger JW; Alpert JE; Fava M
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):772-7. PubMed ID: 19574030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder.
    Iosifescu DV; Greenwald S; Devlin P; Perlis RH; Denninger JW; Alpert JE; Fava M
    Acta Psychiatr Scand; 2008 Apr; 117(4):271-6. PubMed ID: 18307587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder.
    Bares M; Brunovsky M; Kopecek M; Novak T; Stopkova P; Kozeny J; Sos P; Krajca V; Höschl C
    Eur Psychiatry; 2008 Aug; 23(5):350-5. PubMed ID: 18450430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study.
    Leuchter AF; Cook IA; Marangell LB; Gilmer WS; Burgoyne KS; Howland RH; Trivedi MH; Zisook S; Jain R; McCracken JT; Fava M; Iosifescu D; Greenwald S
    Psychiatry Res; 2009 Sep; 169(2):124-31. PubMed ID: 19712979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled study.
    Kaplan EM
    Clin Ther; 2002 Jul; 24(7):1194-200. PubMed ID: 12182262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo.
    Entsuah AR; Huang H; Thase ME
    J Clin Psychiatry; 2001 Nov; 62(11):869-77. PubMed ID: 11775046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frontal and rostral anterior cingulate (rACC) theta EEG in depression: implications for treatment outcome?
    Arns M; Etkin A; Hegerl U; Williams LM; DeBattista C; Palmer DM; Fitzgerald PB; Harris A; deBeuss R; Gordon E
    Eur Neuropsychopharmacol; 2015 Aug; 25(8):1190-200. PubMed ID: 25936227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two items on the Hamilton Depression rating scale are effective predictors of remission: comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine.
    Silverstone PH; Entsuah R; Hackett D
    Int Clin Psychopharmacol; 2002 Nov; 17(6):273-80. PubMed ID: 12409680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of venlafaxine versus specific serotonin reuptake inhibitors in treatment of major depressive disorder: a meta-analysis of published studies.
    de Silva VA; Hanwella R
    Int Clin Psychopharmacol; 2012 Jan; 27(1):8-16. PubMed ID: 21971532
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of venlafaxine in the treatment of major depressive disorder according to baseline severity.
    Schmitt AB; Bauer M; Volz HP; Moeller HJ; Jiang Q; Ninan PT; Loeschmann PA
    Eur Arch Psychiatry Clin Neurosci; 2009 Sep; 259(6):329-39. PubMed ID: 19255709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
    Lenox-Smith AJ; Jiang Q
    Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depression-free days as a summary measure of the temporal pattern of response and remission in the treatment of major depression: a comparison of venlafaxine, selective serotonin reuptake inhibitors, and placebo.
    Mallick R; Chen J; Entsuah AR; Schatzberg AF
    J Clin Psychiatry; 2003 Mar; 64(3):321-30. PubMed ID: 12716275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EEG microstates as markers of major depressive disorder and predictors of response to SSRIs therapy.
    Lei L; Liu Z; Zhang Y; Guo M; Liu P; Hu X; Yang C; Zhang A; Sun N; Wang Y; Zhang K
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Jun; 116():110514. PubMed ID: 35085607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual reuptake inhibitors incur lower rates of tachyphylaxis than selective serotonin reuptake inhibitors: a retrospective study.
    Posternak MA; Zimmerman M
    J Clin Psychiatry; 2005 Jun; 66(6):705-7. PubMed ID: 15960562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venlafaxine extended-release for depression following spinal cord injury: a randomized clinical trial.
    Fann JR; Bombardier CH; Richards JS; Wilson CS; Heinemann AW; Warren AM; Brooks L; McCullumsmith CB; Temkin NR; Warms C; Tate DG;
    JAMA Psychiatry; 2015 Mar; 72(3):247-58. PubMed ID: 25607727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early change of prefrontal theta cordance and occipital alpha asymmetry in the prediction of responses to antidepressants.
    Bares M; Novak T; Vlcek P; Hejzlar M; Brunovsky M
    Int J Psychophysiol; 2019 Sep; 143():1-8. PubMed ID: 31195067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of vortioxetine versus venlafaxine XR in adults in Asia with major depressive disorder: a randomized, double-blind study.
    Wang G; Gislum M; Filippov G; Montgomery S
    Curr Med Res Opin; 2015 Apr; 31(4):785-94. PubMed ID: 25650503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Escitalopram but not placebo modulates brain rhythmic oscillatory activity in the first week of treatment of Major Depressive Disorder.
    Leuchter AF; Hunter AM; Jain FA; Tartter M; Crump C; Cook IA
    J Psychiatr Res; 2017 Jan; 84():174-183. PubMed ID: 27770740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hyponatremia associated with selective serotonin reuptake inhibitors, mirtazapine, and venlafaxine in Korean patients with major depressive disorder.
    Jung YE; Jun TY; Kim KS; Bahk WM
    Int J Clin Pharmacol Ther; 2011 Jul; 49(7):437-43. PubMed ID: 21726494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.